加载中
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
收盘时
US$1.83
−US$0.04 · -2.14%
盘后
US$1.8577
+US$0.0277 · +1.51%
10月12日 19:59 ET
盘中时间采用ET。市场数据可能有所延迟。
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
日内区间
当前US$1.83
52周区间
当前US$1.83
盘中时间采用ET。市场数据可能有所延迟。
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
日内区间
当前US$1.83
52周区间
当前US$1.83
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 3267.2万 USD | 1270.9万 USD | 322.9万 USD | 537.74万 USD | 2514.74万 USD |
| 销售、一般及管理费用 | 2371.3万 USD | 678.5万 USD | 500.5万 USD | 567.52万 USD | 758.08万 USD |
| 营业费用 | 5638.5万 USD | 1949.4万 USD | 823.4万 USD | 1105.26万 USD | 3272.82万 USD |
| 利息收入 | 381.9万 USD | 191.4万 USD | — | — | — |
| 利息支出 | — | 2.3万 USD | 2.4万 USD | 4443 USD | 949 USD |
| 折旧和摊销 | — | — | 8000 USD | 11.33万 USD | 10.9万 USD |
| 营业利润 | −5638.5万 USD | −1949.4万 USD | −823.4万 USD | −1105.26万 USD | −3272.82万 USD |
| 净利润 | −5259.9万 USD | −1760.2万 USD | −771.1万 USD | −1104.79万 USD | −3247.44万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$4.40
上涨空间 140.44%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年1月3日 | 1:80 | — | — |
股票拆分 | 2023年1月5日 | 1:20 | — | — |
股票拆分 | 2018年2月26日 | 1:20 | — | — |
股票拆分 | 2013年5月13日 | 1:20 | — | — |
股票拆分 | 2009年11月9日 | 1:15 | — | — |
已生效 2024年1月3日
1:80
已生效 2023年1月5日
1:20
已生效 2018年2月26日
1:20
已生效 2013年5月13日
1:20
已生效 2009年11月9日
1:15
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM174.15万0.00%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Total Stock Market ETFVTI156.82万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF51.47万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO26.53万0.00%180亿 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC21.37万0.02%13.17亿 USD0.60%US$181.66-0.73%
Fidelity Enhanced Small Cap ETFFESM11.58万—64.1亿 USD0.28%US$45.24-0.48%
ALPS Medical Breakthroughs ETFSBIO8.82万0.05%1.91亿 USD0.50%US$53.85-2.16%
Dimensional - US Core Equity 2 ETFDFAC6.14万0.00%885.96亿 USD0.21%US$45.31-0.04%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMALPS Medical Breakthroughs ETFSBIODimensional - US Core Equity 2 ETFDFACAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
